IL-23
![](https://pbs.twimg.com/profile_images/1324821320429981703/dAiq_hpT.jpg)
![](https://pbs.twimg.com/media/EmY-X1QXMAEYSzM.jpg)
![](https://pbs.twimg.com/profile_images/996072082994843650/-ZFXC20E.jpg)
![](https://pbs.twimg.com/media/EmUVEw4XMAMzXMy.jpg)
![](https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg)
1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap
![](https://pbs.twimg.com/media/EmUi4T2XEAI5HcI.png)
![](https://pbs.twimg.com/profile_images/1702756729/image.jpg)
Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis https://t.co/hgPDtFRxer #PsA #Guselkumab
![](https://pbs.twimg.com/profile_images/1324821320429981703/dAiq_hpT.jpg)
![](https://pbs.twimg.com/media/EmKoXxBXIAIuq0t.jpg)
![](https://pbs.twimg.com/profile_images/1324821320429981703/dAiq_hpT.jpg)
DISCOVER-2 (52 wk study) Guselkumab 100mg q4wk and q8wk for tx of PsA 1️⃣Sustained responses in: ACR20/50/70, PASI90/100, HAQ-DI, MDA/VLDA, QoL 2️⃣Improvement enthesitis/dactylitis 3️⃣No increase rate of serious infection @RheumNow #ACR20 Abs#0506 https://t.co/7MXYTucVZ9
![](https://pbs.twimg.com/media/EmKtxC6WkAATHVa.jpg)
San Francisco-based rheumatologist Dr. Lianne Gensler examines a wide range of spondyloarthritis topics at ACR 2020, including how to join up with others interested in spondyloarthritis; enthesitis; the utility of MRI for the diagnosis for axSpA; novel treatments; and the impact of drugs on disease modification.